Clinuvel Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Clinuvel Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Clinuvel Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Clinuvel Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Clinuvel Pharmaceuticals Ltd (Clinuvel) is a global speciality pharmaceutical company. The company is primarily focused on developing and commercializing innovative treatments for unmet medical needs for the treatment of patients with genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for the general population. Its lead product, Scenesse (afamelanotide), is a systemic photoprotective drug used for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). Clinuvel's products are primarily aimed at patients with acute and chronic medical conditions where no alternatives exist, particularly in the fields of skin and brain disorders. Its main activities include research and development of melanocortin-based products. The company's products are primarily used by patient populations requiring systemic photoprotection, DNA repair, repigmentation, and treatment for acute or life-threatening conditions. It operates in various regions, including Europe, the US, Israel, and Australia. Clinuvel is headquartered in Victoria, Melbourne, Australia.
Headquarters
Australia
Address
Level 22, 535 Bourke Street, Melbourne, Victoria, 3000
Website
www.clinuvel.com
Telephone
61 3 96604900
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CUV (ASX)
Revenue (2025)
$62.7M
7.8%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
1.5%
(2025 vs 2024)
Market Cap*
$357.5M
Net Profit Margin (2025)
XYZ
-5.8%
(2025 vs 2024)
* As of and is in US$
Clinuvel Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Scenesse (afamelanotide 16mg implant) |
| Parvysmelanotide (VLRX001) |
| Prenumbra |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Corporate Changes/Expansions | In December, the company announced the expansion of its VALLAURIX Research, Development and Innovation Center in Singapore. |
| 2025 | Contracts/Agreements | In January, the company entered into a distribution agreement with Diligens Salud SA for its drug SCENESSE (afamelanotide). |
| 2024 | Contracts/Agreements | In August, the company entered into a partnership with Tareen Dermatology to conduct advanced-stage clinical trials for an innovative treatment for vitiligo. |
Competitor Comparison
| Key Parameters | Clinuvel Pharmaceuticals Ltd | UCB SA | Biofrontera AG | Sol-Gel Technologies Ltd | Opthea Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Belgium | Germany | Israel | Australia |
| City | Melbourne | Anderlecht | Leverkusen | Ness Ziona | Melbourne |
| State/Province | Victoria | Bruxelles-Capitale | Nordrhein-Westfalen | - | Victoria |
| No. of Employees | 100 | 10,117 | 76 | 34 | 4 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter Vaughan | Chief Financial Officer | Senior Management | 2024 | - |
| Dr. Dennis Wright | Chief Scientific Officer | Senior Management | 2005 | - |
| Lachlan Hay | Chief Operations Officer | Senior Management | 2024 | - |
| Jeffrey V. Rosenfeld | Chairman | Non Executive Board | 2024 | - |
| Dr. Karen Agersborg | Director; Managing Director | Executive Board | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer